CVS Caremark shares could reach $85 in a year, Barron's says CVS Caremark's move to stop selling tobacco products should bring in healthcare contract renewals, which more than make up for the EPS loss from tobacco sales. The stock could rise to $85 in a year, Barron's argues in a feature article. The company has a healthy dividend yield and buyback program, the paper adds. Reference Link
Leerink healthcare technology analyst holds analyst/industry conference call Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.